Akeso’s 2026 interim results show record‑high drug sales and progress on its IO 2.0 strategy, advancing bispecific ADCs in oncology, immunology and Alzheimer’s
Executive summary: Akeso announced its 2026 interim results, reporting record‑high drug sales revenue and advancing its IO 2.0 strategy with progress on bispecific ADC programs in oncology, immunology and Alzheimer’s. The results demonstrate strong commercial traction and pipeline advancement, which could drive future revenue growth and investor confidence in Akeso’s competitive position.
Who is involved: Akeso, Inc. (ticker 9926.HK), its executive team, investors, and collaborators in ADC and Alzheimer’s research.
Likely next: Continued clinical development of bispecific ADCs, potential regulatory filings, and expansion of commercial sales efforts.
Akeso’s 2026 interim results showed record‑high drug sales revenue, underscoring commercial success. The company reported progress on its global immuno‑oncology 2.0 (IO 2.0) strategy, including advancements in bispecific antibody‑drug conjugate (ADC) programs targeting oncology, immunology and Alzheimer’s disease. These developments expand Akeso’s pipeline and reinforce its positioning in the competitive biotech sector.
Timeline
- — Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's (PR Newswire)
- — Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline (PR Newswire)
- — ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire)
- — Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer (PR Newswire)
- — Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer (PR Newswire)
Key entities
Sources
- Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's — PR Newswire
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline — PR Newswire
- Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer — PR Newswire
- Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer — PR Newswire
- ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates — PR Newswire
Related cases
- Akeso's B7‑H3 ADC AK157D1 gains Phase I clearance, adding a third differentiated candidate to its oncology pipeline
- Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation
- Akeso advances its IO2.0/ADC2.0 strategy with first patient dosed in Phase II trial of AK146D1 combined with ivonescimab for breast cancer
- GlycoNex initiates first-in-human Phase I trial of its glycan-targeted ADC GNX1021 in Japan
- Akeso initiates first‑in‑human trial of its HER3‑targeted ADC combined with Ivonescimab in lung cancer, advancing its IO2.0+ADC2.0 pipeline
- Mabwell's ESMO 2026 oral presentation of clinical data for its Nectin-4-targeting ADC 9MW2821 highlights potential progress in triple-negative breast cancer therapy and could affect oncology investment sentiment